// App-Quantinova.ai

P316 : Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North

Researchers

Presenter

  • Sands, B.E

Principal Investigators

  • Dignass, A

  • Irving, P

  • Chiorean, M

  • Long, M

  • Eren, D

  • Ahmad, H.A

  • Osterman, M.T

  • Petersen, A

  • Elegbe, A

  • Ritter, T

  • Danese, S

Medical Centers

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Goethe University, Gastroenterology, Frankfurt, Germany

  • Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom

  • Swedish Medical Center, Gastroenterology, Seattle, United States

  • UNC Chapel Hill, Gastroenterology, Chapel Hill, United States

  • Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States

  • GI Alliance, Gastroenterology, Southlake, United States

  • IRCCS Ospedale and Universit Vita-Salute San Raffaele, Milano, Italy

Locations

  • United States

  • Germany

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

  • Ozanimod

  • Mesalamine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved